Urology M&A Advisory
For multi-physician urology practices, integrated platforms with lab and radiation therapy services, and groups with surgical center ownership. Urology PE consolidation has accelerated significantly since 2020, with multiple well-capitalized platforms competing for quality practices.
Speak with an advisor: (800) 815-0590How We Help Urology Sellers
Capital Partners' M&A framework is built around the specific dynamics of middle-market specialty practice transactions. The three engagement profiles below cover most of how urology practice owners come to us.
Five to twenty-five physician practices with established procedural volume, sub-specialty mix, and operational infrastructure. The middle-market urology buyer landscape is active and competitive.
Discuss your practice →Urology practices with owned pathology labs, in-office dispensing, radiation therapy services, and surgical center affiliations achieve significantly higher valuations through diversified EBITDA.
Discuss your platform →Practices with depth in prostate cancer treatment, female urology, pediatric urology, or kidney stones generate buyer interest. Sub-specialty breadth and depth both contribute to valuation.
Discuss your group →Market Context
Urology has emerged as one of the more active specialty consolidation categories since 2020. Major PE-backed platforms including Solaris Health, US Urology Partners, United Urology Group, and Urology America actively acquire practices. The competitive dynamic creates real pricing tension for quality middle-market groups.
The Capital Partners Approach
The active urology platform landscape means quality sellers have real choice among institutional buyers. The differences between platforms in terms of culture, clinical autonomy, growth strategy, and equity participation matter materially over the multi-year rollover hold period. A deliberate process surfaces the right combination of price, terms, and platform fit.
Urology groups considering institutional capital benefit from operational preparation — clean financials, articulated ancillary strategy, and clear physician compensation structure. The valuation lift from preparation typically exceeds the cost meaningfully.
Valuation Drivers
Urology practice valuation is driven by a specific set of operational, clinical, and structural factors. Below are the elements buyers evaluate most carefully when developing valuation and offer terms.
Owned pathology labs and integrated lab services contribute to total practice EBITDA. Pathology revenue is among the highest-margin ancillary services in urology.
Practices with integrated radiation therapy services (particularly for prostate cancer treatment) achieve meaningful valuation premiums through the diversified revenue base.
Surgical volume, complexity, and case mix all factor into buyer evaluation. Surgery center ownership or affiliation contributes meaningfully to overall valuation.
Sub-specialty mix across prostate cancer, female urology, pediatric urology, urologic oncology, and stones influences buyer interest. Sub-specialty depth is valued.
Physician count, sub-specialty distribution, tenure, and post-close commitments all factor into buyer evaluation. Physician roster stability is a primary buyer concern.
In-office dispensing programs for urology medications contribute to ancillary revenue. Buyers value the recurring medication dispensing revenue stream.
Begin a Conversation
The most useful next step is a confidential conversation. We'll listen to your situation, give you a directional view of where your practice sits in the current market, and explain how a Capital Partners engagement would actually run. Every conversation begins under NDA.
(800) 815-0590